The clinical success of immune checkpoint therapy (ICT) has produced explosive growth in
tumor immunology research because ICT was discovered through basic studies of immune …

Dendritic cells (DCs) are key orchestrators of immune responses. A specific DC subset,
conventional type 1 DCs (cDC1s), has been recently associated with human cancer patient …

Cancer immunotherapy harnesses the ability of the immune system to recognize and
eliminate cancer. The potent ability of dendritic cells (DCs) to initiate and regulate adaptive …

Dendritic cells (DCs) efficiently process and present antigens to T cells, and by integrating
environmental signals, link innate and adaptive immunity. DCs also control the balance …

Throughout the last decades, dendritic cell (DC)-based anti-tumor vaccines have proven to
be a safe therapeutic approach, although with inconsistent clinical results. The functional …

Dendritic cells (DCs) are endowed with a unique potency to prime T cells, as well as to
orchestrate their expansion, functional polarization and effector activity in non-lymphoid …

Dendritic cells (DCs) are professional antigen-presenting cells, orchestrating innate and
adaptive immunity during infections, autoimmune diseases, and malignancies. Since the …

In cancer patients, dendritic cells (DCs) in tumor-draining lymph nodes can present antigens
to naive T cells in ways that break immunological tolerance. The clonally expanded progeny …

Dendritic cells (DCs) constitute a complex network of cell subsets with common functions but
also with many divergent aspects. All dendritic cell subsets share the ability to prime T cell …

Dendritic cells (DCs) are a heterogeneous group of antigen-presenting innate immune cells
that regulate adaptive immunity, including against cancer. Therefore, understanding the …